Phase Ib Study of Safety, Tolerability and Pharmacokinetics of Elpida Once Weekly in Healthy Volunteers

Phase Ib, Single-Center, Randomized Study of Safety, Tolerability and Pharmacokinetics of Elpida in Healthy HIV-Uninfected Volunteers

A randomized once weekly dose for 8 weeks, study in Healthy HIV-Uninfected Volunteers. Each of 3 parallel groups (40 mg, 80 mg and 160mg) enrolls 12 subjects.

Study Overview

• Status: Completed
• Conditions: HIV Infections
• Intervention / Treatment: Drug: Elpida

Detailed Description

The study aims to assess safety, tolerability and PK of once weekly administration of Elpida in different doses.

• Study Type: Interventional
• Enrollment (Actual): 36
• Phase: Phase 1

Contacts and Locations

Study Locations

• Russian Federation
  • Moscow, Russian Federation, 119991
    • Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Men and women aged 18 to 55 years;
2. Verified diagnosis "healthy" according to medical history, physical examination, assessment of vital signs, electrocardiography (ECG), investigations performed in the last 14 days prior to the first administration of IP;
3. Body mass index (BMI) from 18.5 kg/m2 to 30 kg/m2 (inclusive), bodyweight of 50 kg or higher;
4. Negative result of alcohol and drug tests;
5. Women must be in postmenopause for at least 2 years, be surgically sterile or use two reliable methods of contraception from the day of screening and until 3 months after the last dose;
6. Men must use two reliable methods of contraception* from the day of screening and until 3 months after the last dose;
7. Ability to understand the meaning of the study and any risks associated with participation. Ability to interact with the investigator, participate and comply with the requirements of the study throughout its duration;
8. Willingness to sign written consent to participate in the study after reading Informed Consent Form with the opportunity to discuss any questions with the investigator (and/or his/her representative).

Exclusion Criteria:

1. Participation in more than one group of investigational therapy;
2. Past or present diseases of the cardiovascular, bronchopulmonary, neuroendocrine, musculoskeletal systems, as well as diseases of the gastrointestinal tract, liver, kidneys, blood that may interfere with achievement of objectives of this study or affect the safety of a volunteer;
3. The values of laboratory and instrumental parameters, beyond the limit of normal ;
4. Past or present diseases or pathologies, including surgical interventions in the gastrointestinal tract that, in the opinion of the Investigator, may affect the absorption, distribution, metabolism or excretion of the investigational product;
5. A systolic pressure of less than 90 mm Hg or greater than 130 mm Hg; diastolic pressure of less than 60 mm Hg or greater than 85 mm Hg; pulse rate of less than 60 bpm or greater than 90 bpm (at screening);
6. Deviations detected during 12-lead ECG, or QT/QTc interval > 450 milliseconds (ms) for men and > 470 ms for women;
7. Administration of any drugs n, including over-the-counter products, herbal, food, dietary or vitamin supplements 14 days before the first administration of the investigational product;
8. Administration of the following drugs for 28 days prior to screening: corticosteroids (any route of administration); IP that inhibit the activity of cytochrome P450 3A4 (CYP3A4; for example, ritonavir and other drugs for human immunodeficiency virus (HIV), ketoconazole, itraconazole, or similar azole antifungals and macrolide antibiotics such as erythromycin), or the use of any drugs with a significant likely effect on functions of organs (for example, barbiturates, omeprazole, cimetidine);
9. Hepatitis B (HBsAg), antibodies to hepatitis C and HIV, a positive test for syphilis;
10. Positive pregnancy test (for women);
11. Acute infectious diseases less than 4 weeks before screening;
12. Unstable sleeping hours (for example, night shift, sleep disorders, insomnia, jet lag, etc.);
13. Signs of alcohol or drug addiction; intake of alcohol or drugs 4 days prior to screening and during the study; smoking cigarettes 3 months prior to screening and during the study; positive drug and/or alcohol test;
14. Complicated allergic history (including intolerance to medication, including hypersensitivity to the active substance/excipients of the investigational drug) and food allergy;
15. Blood/plasma donation (450 mL of blood or plasma or more) less than 2 months before screening;
16. Participation in another clinical study or administration of any investigational products less than 3 months before screening;
17. Any other concomitant medical or significant mental conditions that render a volunteer unsuitable for participation in the clinical study;
18. A volunteer who is considered for enrollment in the study is an employee of the study site or company of the Sponsor or a member of an employee's family

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: SEQUENTIAL
• Masking: NONE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Elpida 40 mg once weekly; elsulfavirine 40mg orally once weekly for 8 weeks	Drug: Elpida; elsulfavirine, capsules; Other Names: elsulfavirine; VM1500; VM-1500
EXPERIMENTAL: Elpida 80 mg once weekly; elsulfavirine 80mg orally once weekly for 8 weeks	Drug: Elpida; elsulfavirine, capsules; Other Names: elsulfavirine; VM1500; VM-1500
EXPERIMENTAL: Elpida 160 mg once weekly; elsulfavirine 160mg orally once weekly for 8 weeks	Drug: Elpida; elsulfavirine, capsules; Other Names: elsulfavirine; VM1500; VM-1500

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of AEs and SAEs	Incidence of AEs and SAEs	77 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
elsulfavirine plasma concentration	elsulfavirine plasma concentration	77 days
VM1500A plasma concentration	active metabolite plasma concentration	77 days

Collaborators and Investigators

• Sponsor: Viriom
• Investigators: Principal Investigator: Elena Smolyarchuk, MD, PhD, Sechenov First Moscow State Medical University

Study record dates

Study Major Dates

• Study Start (ACTUAL): December 18, 2018
• Primary Completion (ACTUAL): April 2, 2019
• Study Completion (ACTUAL): April 2, 2019

Study Registration Dates

• First Submitted: January 10, 2022
• First Submitted That Met QC Criteria: January 10, 2022
• First Posted (ACTUAL): January 24, 2022

Study Record Updates

• Last Update Posted (ACTUAL): January 24, 2022
• Last Update Submitted That Met QC Criteria: January 10, 2022
• Last Verified: January 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; Immunologic Deficiency Syndromes; Immune System Diseases; HIV Infections; Anti-Infective Agents; Antiviral Agents; Anti-HIV Agents; Anti-Retroviral Agents; Elsulfavirine
• Other Study ID Numbers: HIV-VM1500-09

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No